I-Lymphoma Australia iphumelele ekufumaneni isibonelelo sehlabathi jikelele esivela kwa-AbbVie ukuqhuba udliwano-ndlebe kunye neengcali zase-Australia kunye namazwe ngamazwe kwi-lymphoma kunye ne-lymphocytic leukemia engapheliyo (CLL). Udliwano-ndlebe luya kuxela ulwazi lwamva nje malunga nolingo lwezonyango lwe-lymphoma/CLL kunye nezifundo ezivela kwihlabathi liphela kwaye zaboniswa ngexesha lentlanganiso ye-ASH. Olu dliwano-ndlebe luya kwabelwana ngalo kwihlabathi jikelele kusetyenziswa amaqela axhasa izigulane.
I-Lymphoma Australia iqhube udliwano-ndlebe oluphantse lube ngama-40 ngeentsuku ezi-4 zentlanganiso kwaye singathanda ukudlulisa umbulelo ongazenzisiyo kuluntu lwe-lymphoma / CLL kuye wonke umntu owabelana nathi ngexesha labo, ulwazi kunye nobuchule kunye nathi.
I-B-cell Lymphoma
UGqr Laurie Sehn – ASH Lymphoma Updates.
UGqr Laurie Sehn ovela kwiZiko loMhlaza laseBritish Columbia waseVancouver, eKhanada nguSihlalo webhodi yeengcebiso zonyango kwi-International Lymphoma Coalition. UGqr Sehn uxoxe ngezinye zeembalasane kwiinoveli zonyango ezathi zanikwa ngexesha lentlanganiso ye-ASH ye-lymphoma. Ezi ziquka i-Polatuzumab (i-antibody drug conjugate) yokusasaza i-B-cell lymphoma (DLBCL) enkulu kunye ne-Mosunetuzumab - (i-antibody bispecific) esetyenziselwa i-B-cell non-Hodgkin lymphomas.UGqr Chan Cheah – iSigaba soku-I soFundo lwe-TG-1701 eBuyelwe kwakhona okanye i-Refractory B-cell Lymphoma.
U-A/Prof Chan Cheah, uMcebisi we-Haematologist, iSibhedlele sikaSir Charles Gairdner, iSibhedlele saBucala saseHollywood kunye noPhando loMhlaza weGazi WA, ePerth, eNtshona Australia, baxoxe ngentetho yepowusta kwi-ASH yolingo olwaqhutywa e-Australia kusetyenziswa isizukulwana esitsha seBruton sikaTyrosine Kinase. (BTK) inhibitor ebizwa ngokuba yi-TG-1701 esetyenziswa kwizigulane ezine-relapsed / refractor B-cell malignancies. Eli yeza lomlomo linikezelwa njenge-arhente enye zidityaniswe ne-umbralisib (PI3K inhibitor) kunye ne-ubiltuximab (i-glycoengineered anti-CD20 monoclonal antibody).UGqr George Uyalandela-Uhlaziyo lweLymphoma.
UGqr George Ulandela iLymphoma/CLL Clinical Lead yaseCambridge kwaye ukwabambe iqela lezithuba ezibandakanya usihlalo weforum yase-UK CLL. UGqr Ulandela uxoxe ngohlaziyo lwe-lymphoma oluthe lwanikezelwa ngexesha lentlanganiso yomdla ye-ASH. Ezi zibandakanya ulingo lwesigaba I kusetyenziswa iyeza elitsha elibizwa ngokuba yi-Monunetuzumab eliyi-bispecific monoclonal antibody ejolise kwi-CD3 kunye ne-CD20 kwaye ikhokelele kwiimpendulo ezihlala ixesha elide kwizigulane ezine-B-cell ebuyela umva okanye i-refractory ye-B-cell non-Hodgkin lymphoma, kubandakanywa izigulane eziphinde zabuyela kwi-CAR T. -unyango lweseli.
UGqr Stephen Schuste – I-Mosunetuzumab yenza uxolelo olupheleleyo oluhlala ixesha elide kwizigulana ezine-B-cell non-Hodgkin lymphoma.
I-bispecific monoclonal antibody i-Mosunetuzumab, ejolise kwi-CD3 kunye ne-CD20, ikhokelele kwiimpendulo ezihlala ixesha elide kwizigulane ezine-B-cell non-Hodgkin lymphoma (NHL), kwanabo babenesifo esiye saphinda sabuyela okanye siphikisana ne-chimeric antigen receptor (CAR) T- unyango lweseli. UGqr Schuste uxoxa ngesigaba esiqhubekayo sophononongo lwe-I/Ib (GO29781; NCT02500407) ye-mosunetuzumab kwizigulane ezine-B-cell non-Hodgkin lymphoma (NHL), ezibuyele umva/i-refractory (R/R) kunyango lwe-CAR-T okanye aba ukulibaziseka kunyango olusebenzayo ayibandakanyi le ndlela. Inkxaso yedatha yokuqala yokuba i-mosunetuzumab inokunyamezela okuthandekayo kunye nokusebenza okuzinzileyo kwi-R/R B-cell ye-NHL enyangwe kakhulu.
UGqr John Leonard - ugqamisa kwintlanganiso ye-lymphoma.
UGqr Leonard uxoxe ngezimvo zakhe zobuchwephesha kwiinkcazo-ntetho ze-lymphoma ngexesha lentlanganiso. Uxoxe ngezihloko ezininzi ezibandakanya: • I-Follicular lymphoma – iirejimeni ezingenayo i-chemo • Ukusasaza i-B-cell Lymphoma enkulu – impilo yamathambo kwizigulane ezisemva kwe-R-CHOP kunye ne-CAR T-cell therapy • I-Mantle Cell Lymphoma – amayeza amatsha adityaniswe ne-chemotherapy • Uvavanyo lwegazi lwe-DNA • Ugonyo lwe-lymphoma
I-Chronic Lymphocytic Leukemia (CLL) kunye neLymphocytic Leukemia encinci (SLL)
UGqr Brian Koffman-uhlaziyo lwe-CLL kunye nenkxaso yesigulana.
UGqr. Koffman, ugqirha owaziwayo, utitshala kunye noprofesa weklinikhi wajika isigulane se-CLL, uzinikele ekufundiseni nasekuncedeni uluntu lwe-CLL ukususela ekuxilongweni kwakhe ngo-2005. UDkt. amava kunye nokuqonda okumvumela ukuba anike iingcaciso ezicacileyo zemiba entsonkothileyo kwaye athethelele abanye abaguli kunye nokwazisa abanye ababoneleli ngezempilo. Oku kubaluleke ngakumbi xa kujongwa imeko yonyango eguquka ngokukhawuleza. UGqr Koffman ngumseki we-CLL Society, eMelika. UDkt Koffman uxoxe ngohlaziyo lwe-CLL kwinkomfa ebandakanya ukuhlaziywa malunga ne-CAR T-cell therapy, ibrutinib, i-acalabrutinib, ukulandelelana kwamayeza kunye nonyango oludibeneyo oludibeneyo. Kwakhona waxoxa ngolawulo olungcono lwe-CLL, kubandakanywa ukuhlolwa kofuzo ngaphambi kokuba unyango kunye nezo zigulana ezinesifo esingaguqukiyo, i-17p del akufanele ibe ne-chemotherapy, kunokuba unyango olujoliswe kuyo.
UNjingalwazi uJohn Gribben kunye noDeborah Sims – Isishwankathelo sonyango lwe-CLL.
UNjing Gribben uxoxe ngembono yakhe ngohlaziyo oluvela kwintlanganiso apho uninzi lweenkcazo-ntetho lubethelele ukuba unyango olusetyenziswayo lulungile njengoko bekukho ukulandelela ixesha elide. Ngokulandela ixesha elide kwakhona kuza nolwazi lwetyhefu entsha enokuthi ibonakale. Sinokuthi emva koko sifundise izigulana ngcono ngokuba nombono ongcono wento emayiyilindele. Ubuye waxoxa ngonyango lwenoveli yesizukulwana esitsha eye yaziswa, hayi kuphela kwi-CLL, kodwa ezinye iilymphoma ezifana neFollicular lymphoma & Mantle cell lymphoma. Kukwakho nolingo lwezonyango lwesigaba sokuqala ngamayeza amatsha abonisa isithembiso. Inkxalabo elandelayo yeyokuba ngolu nyango lulutsha kunye nonyango oludibeneyo, kuza neendleko ezongeziweyo kwiinkqubo zempilo.
UProf Stephan Stilgenbauer noDeborah Sims – Uhlaziyo kulawulo lwe-CLL/SLL.
UProf Stilgenbauer unike isishwankathelo sohlaziyo lonyango lwezigulane ezine-CLL/SLL ezivela kwintlanganiso ye-ASH. Uxoxa ngokusetyenziswa kweendlela ezintsha zonyango njengee-agent ezingatshatanga kunye nezidibeneyo ezineziphumo ezibalulekileyo kwizigulane, ngakumbi abo banesifo esingaguqukiyo kwaye ngoko abaphenduli kulawulo olusekelwe kwi-chemotherapy yendabuko. Unyango lwexesha elizayo lwe-CLL/SLL inokuba ichemotherapy inokuba lunyango lwesibini okanye lwesithathu.
A/Prof Constantine Tam kunye noDeborah Sims – CLL & Mantle Cell Lymphoma.
A/Prof Constantine Tam, Peter MacCallum Cancer Centre, RMH & St Vincent's Hospital wathetha noDeborah Sims, waseLymphoma Australia. UGqr Tam unikezela ngezimvo zakhe kwiingongoma eziphambili kwintlanganiso ye-CLL kunye ne-Mantle cell lymphoma. Unike isishwankathelo seenkcazo-ntetho zakhe ezi-3 ezinconyiweyo zeChronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL).
UGqr George Uyalandela-uhlaziyo lwe-CLL.
UGqr George Follows wase-UK uthethe ne-Lymphoma Australia kwintlanganiso ye-American Society of Hematology (ASH) ebibanjwe kutshanje e-Orlando, e-USA. UGqr Follows yiLymphoma/CLL Clinical Lead yaseCambridge kwaye ukwabambe iqela lezithuba ezibandakanya usihlalo weforum yase-UK CLL. Uxoxe ngohlaziyo lophando lwamva nje kunye neziphumo zophononongo ezithiwe thaca kwintlanganiso ye-ASH kwi-CLL.
UDkt Nitin Jain kunye noDeborah Sims - Ibrutinib & Venetoclax kwizigulane ezine-CLL.
UGqr Nitan Jain yiNjingalwazi eNxulumeneyo kwiSebe leLeukemia kwiYunivesithi yaseTexas iMD Anderson Cancer Centre eHouston, eTexas, eMelika. UGqr Nitan uxoxe ngeentetho zakhe ze-2 ngexesha lentlanganiso ye-ASH yezifundo ze-2 eziqhutywe kwi-MD Anderson Cancer Centre usebenzisa i-Ibrutinib edibeneyo kunye ne-venetoclax kunye nezigulane ezine-lymphocytic leukemia engapheliyo (CLL) kuzo zombini unyango lokuqala kunye nalabo abanesifo esiphindaphindiweyo / esichasayo. Iziphumo zibonise ukuba kumaqela omabini unyango oludibeneyo usebenzisa i-ibrutinib kunye ne-venetoclax yindlela yomlomo esebenzayo ye-chemotherapy-free kwizigulane ezine-CLL kunye nezifundo eziqhubekayo ziya kuqhubeka.
UGqr Tanya Siddiqi – I-CAR T-cell kwi-CLL ebuyiselweyo/e-refractory.
UGqr Tanya Siddiqi unguMlawuli, iNkqubo ye-Chronic Lymphocytic Leukemia, iZiko le-Toni Stephenson Lymphoma kunye ne-A/Prof yeSebe le-Hematology kunye ne-Hematopoietic Transplantation kwi-City of Hope National Medical Centre, e-Duarte, e-USA. UGqr Siddiqi uxoxe ngenkcazo-ntetho yakhe ngexesha lentlanganiso yesigaba I sokufunda ukunyanga izigulana ezibuyele emva okanye ezichasayo nge-CLL. Zonke izigulane ngaphambili zafumana ubuncinane unyango oluqhelekileyo lwe-3, kuquka i-ibrutinib kunye nesiqingatha sezigulane nazo zafumana i-venetoclax. Uphononongo lunyange izigulane ze-23 nge-CAR T-cell therapy apho ngaphezu kwe-80% yafumana iimpendulo ezihlala ixesha elide kwiinyanga ze-6. Ukulandelela kuyaqhubeka.
UNjingalwazi uJohn Seymour – Isishwankathelo sophononongo lwaseMurano – CLL/SLL.
UNjingalwazi Seymour ubonise uhlalutyo lweminyaka emine yophononongo lweMurano oluqinisekisa inzuzo ezinzileyo yexesha elilinganiselweyo iVenetoclax & rituximab kwi-relapsed or refractory chronic lymphocytic leukemia (CLL). I-Venetoclax (i-Ven) i-inhibitor yomlomo ekhethiweyo kakhulu ye-key apoptosis regulator BCL-2, egxininiswe kakhulu kwi-CLL. I-MURANO (uphando lweSigaba sesi-III esingenamkhethe) luthelekisa ixesha elimiselweyo leVenR kunye ne-bendamustine-rituximab eqhelekileyo (BR) kwi-R/R CLL. Ukusinda okuphezulu kwe-progression-free survival (PFS) ye-VenR ngokuchasene ne-BR yasekwa kuhlalutyo lokuqala olucwangcisiweyo (Seymour et al. N Engl J Med 2018); Inzuzo eqhubekayo ye-PFS yabonwa ngokulandelwa kwexesha elide kwaye emva kokuba zonke izigulane zigqibe unyango.
UNjingalwazi uPeter Hillmen – Imiceli-mngeni kwinkangeleko yonyango ye-CLL/SLL.
UProf Hillman uxoxa ngeminye yemingeni yemeko yonyango eguqukayo ngokukhawuleza ye-CLL/SLL kunye nonyango oluninzi olukwimarike.
UNjingalwazi uPeter Hillmen - uhlaziyo lwe-CLL ukusuka kwi-ASH 2019.
UNjingalwazi u-Hillmen uxoxe ngamanye amagqabantshintshi abalulekileyo avela kwintlanganiso yolingo lwenoveli yonyango olusetyenziswe kwindawo ephambili eyathi yaboniswa ebonisa iziphumo ezilungileyo ngokusetyenziswa kwe-ibrutinib (BTK inhibitor), i-acalabrutinib (isizukulwana esitsha se-BTK inhibitor), i-venetoclax (BCL2 inhibitor). ) kunye nokusetyenziswa konyango oludibeneyo. Kwakhona waxoxa ngezilingo zeklinikhi kwimeko ephindaphindiweyo ebonisa iziphumo ezilungileyo ezibandakanya unyango lwe-CAR T-cell. Enkosi kuKhathalelo lweLeukemia ngokwabelana nodliwanondlebe kunye neLymphoma Australia.
UProf Miles Prince – uvavanyo lweGenetic (CLL/SLL) kunye nonyango lwe-CAR T-cell.
UNjingalwazi Prince uxoxe ngezimvo zakhe ngezihloko eziphambili ezinomdla kwi-lymphoma kwintlanganiso. Uxoxe ukuba eyona ndlela ilungileyo yokunyanga i-lymphoma yesigulana, ukuxilongwa kwabo kufuneka kuqondwe kwaye kwaziwe ngokupheleleyo. Kuye kwaboniswa ukuba izigulane ezifunyanwe ukuba zine-CLL / SLL kufuneka zihlolwe ngofuzo ngaphambi kokufumana unyango. Izigulane ezingaguqukiyo kunye ne-TP53 eguqulweyo ye-CLL / SLL, i-chemotherapy ibonakaliswe ukuba ayisebenzi kakuhle kweli qela lesigulane. E-USA nase-UK (kunye namanye amazwe aseYurophu) izigulane zixhaswa ngemali ukuze zifumane i-Ibrutinib front-line, nangona kunjalo oku akusenjalo e-Australia, apho izigulane zifumana i-chemo-immunotherapy kunye ne-ibrutinib kunyango lwesibini.
Ukusasaza i-B-cell Lymphoma enkulu (DLBCL)
A/Prof Chan Cheah – Aggressive Lymphoma, Diffuse Large B Cell lymphomas.
U-A/Prof Cheah uhlaziya iphepha elithi “Aggressive Lymphoma (Diffuse Large B-cell and other aggressive b-cell non-Hodgkin lymphomas) – iziphumo zovavanyo lweklinikhi olulindelekileyo: ukwenza i-frontline chemotherapy” iseshini ebibanjwe ngeCawa ye-8 kaDisemba e-ASH ka-2019.
UGqr Jason Westin – Ukusasaza uhlaziyo olukhulu lwe-B-cell Lymphoma kunye neSifundo sokuQala esiSmart.
UGqr Westin uxoxe ngezinye zeembalasane ezivela kwinkomfa ye-DLBCL kuquka unyango lwe-CAR T-cell kunye nohlaziyo oluvela kwizifundo ezisebenzisa i-chemotherapy encinci kwaye ngoko ke ukuphucula iziphumo zecala ezinetyhefu kwizigulane.
I-Lymphoma yesifo
UGqr Loretta Nastoupil – Isifundo seFollicular lymphoma – iCandelo loku-1.
UGqr Nastoupil exoxa ngeziphumo zesigaba sakhe se-II sophando lwe-Obintuzumab (uhlobo lwe-II anti-CD20 monoclonal antibody) kunye ne-Lenalidamide (i-immunomodulatory agent) kwindawo engazange iphathwe ngaphambili, i-tumor umthwalo ophezulu we-FL. Olu luhlu lwezonyango lubonwe lunyamezelwa kakuhle kwaye lusebenza kakuhle kwisifundo sangaphambili kwizigulane eziphathwe ngokuphindaphindiweyo okanye i-refractory FL.
UGqr Loretta Nastoupil – Isifundo seFollicular lymphoma – iCandelo loku-2.
UGqr Nastoupil uxoxe ngeziphumo zesigaba sakhe se-II sophando lwe-Obintuzumab (uhlobo lwe-II anti-CD20 monoclonal antibody) kunye ne-Lenalidamide (i-immunomodulatory agent) kwindawo engazange iphathwe ngaphambili, i-tumor umthwalo ophezulu we-FL. Uphononongo olongezelelweyo lwale ndlela isebenzayo, yonyango lwe-immune kwi-FL engaphathwanga ifanelekile. UGqr.
A/Prof Chan Cheah – Uhlaziyo lwelingo lwezonyango lwe-Follicular lymphoma.
UGqr Cheah uxoxe ngentetho enikwe nguGqr Loretta Nastoupil ovela kwi-MD Anderson Cancer Centre, eTexas ngexesha lentlanganiso ye-ASH 2019. Uphononongo lwesigaba sesi-II lujonge ukunyanga izigulane ze-Follicular lymphoma ezinganyangwanga ngaphambili kunye ne-Obintuzumab (uhlobo lwe-II anti-CD20 monoclonal antibody) kunye ne-Lenalidamide (i-immunomodulatory agent), enomthwalo ophezulu we-tumor. Le ndibaniselwano yonyango ibonwe inyamezeleke kakuhle kwaye iyasebenza kwisifundo sangaphambili kwizigulane ezinyangwa kwi-FL ehlaselweyo okanye i-refractory eqhutywe kwi-MD Anderson Cancer Centre nguProf Nathan Fowler (uphando oluQHELEKILEYO).
UGqr Allison Barraclough -Nivolumab + Rituximab kwi-First-line Follicular Lymphoma.
UGqr Barraclough uxoxe ngeziphumo zethutyana zophononongo lokuqala lwenqanaba lehlabathi le-II, elikhokelwa nguGqr Eliza Hawkes, ulawulo lwangaphambili lwezigulane ezinenqanaba le-1-3A le-follicular lymphoma. Uphononongo lusebenzisa indibaniselwano yonyango lokhuselo lomzimba olusondelayo kuphela, olwalukhe lwazanywa ngaphambili kwisimo esibuyele umva. Izigulane zifumana i-nivolumab kuphela kwiiveki zokuqala ze-8 kwaye ukuba zifezekisa impendulo epheleleyo, ziya kuqhubeka ne-agent eyodwa ye-nivolumab. Kwabo bafumene impendulo eyinxenye kuphela baya kuba nendibaniselwano kwi-nivolumab kunye ne-rituximab. Iziphumo zazilungile kwireyithi yokuphendula ngokubanzi (ORR) ye-80% kwaye ngaphezu kwesiqingatha sezi gulane zifumene impendulo epheleleyo (CR). Kwakukho iprofayili yetyhefu ephantsi, apho izigulane ezininzi zazisakwazi ukusebenza kwaye ziqhubeke nemisebenzi eqhelekileyo yobomi
Ingubo yeseli Lymphoma
UGq Sasanka Handunetti – Mantle Cell Lymphoma (Uhlaziyo lwesifundo se-AIM).
UGqr Handunetti uxoxe ngenkcazo yakhe malunga nohlaziyo lweminyaka emithathu yesigaba se-II sophando lwe-AIM (TAM, et al, NEJM 2018) eqhutywe ePeter MacCallum Cancer Centre eMelbourne, usebenzisa i-BTK inhibitor ibrutinib kunye ne-BCL-2 inhibitor venetoclax therapy kwizigulane ezine I-prognosis embi i-mantle cell lymphoma (MCL). Iziphumo zibonise ukuqhubela phambili kwe-median ukusinda simahla kweenyanga ezingama-29. Iphakamise umbuzo wokuba kukho ithuba lexesha elilinganiselweyo lonyango ekujoliswe kuyo kulawulo lwe-MCL ebuyele umva okanye echasayo.
UNjingalwazi uSteven Le Gouill – Isifundo seMantle Cell Lymphoma.
UNjingalwazi uLe Gouill uxoxe ngesigaba sakhe sokufunda nge-MCL esanda kufunyaniswa esebenzisa i-Ibrutinib, i-Venetoclax kunye ne-Obintuzumab zonke eziye zaboniswa ngaphambili ukuba zisebenza ngokuphindaphindiweyo kwi-refractory setting njenge-arhente enye kunye nokudityaniswa kwi-MCL ephindaphindayo / ephikisayo (R / R) . Kwakhona wanikezela umboniso womgangatho wokunyamekela izigulane ezine-MCL kwisigulane esincinci kunye nesigulane esidala kumgca wangaphambili kunye nolawulo lwe-R / R.
UNjingalwazi uSimon Rule – Uhlaziyo lweMantle Cell Lymphoma.
UProf Simon Rule uxoxe ngenkcazo yepowusta yakhe kwintlanganiso ejonge ukulandelwa kwe-7.5 ngonyaka wezigulane ezine-MCL eziphindaphindayo okanye i-refractory izigulane kwi-ibrutinib (BTK inhibitor) ebonisa inani elibalulekileyo lezigulane ezisekho ekuxolweni ngaphezu kweminyaka eyi-5. Kwakhona kwabonisa ukuba izigulane ezifumene i-Ibrutinib kwimigca yonyango yangaphambili zinempendulo engcono ehlala ixesha elide, kunabo bayifumana i-lateistique.
I-KTE-X19: I-CAR T-Cell Option ye-Mantle Cell Lymphoma?
Amashumi alithoba anesithathu ekhulwini ezigulane ezine-relapsed/refractory mantle cell lymphoma (MCL) ziphendule kunyango nge-KTE-X19, i-autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, ngokweziphumo zolingo lwe-ZUMA-2 olunikezelweyo. kwiNtlanganiso yoNyaka ka-2019 ye-ASH.
IHodgkin Lymphoma
UGqr Jessica Hochberg – Unyango lweKhemotherapy, abantu abadala abancinci kunye neHodgkin Lymphoma.
Amazinga okunyanga i-Hodgkin Lymphoma esanda kufunyaniswa aphezulu ngokusetyenziswa okudibeneyo kwe-chemoradiotherapy. Nangona kunjalo, oku kuhlala kukhokelela ekusebenzeni kakubi ngokomzimba nangokwengqondo okunokuthi kube nefuthe elibonakalayo kumgangatho wobomi phakathi kwabasindileyo. Ukongezwa kwe-Brentuximab vedotin kunye ne-Rituximab kumngcipheko wokudibanisa i-chemotherapy (ngaphandle kwe-cyclophosphamide, etoposide okanye i-bleomycin) kwi-Hodgkin Lymphoma esanda kuxilongwa ibonakala ikhuselekile kubantwana, abaselula kunye nabaselula. Iziphumo zethu zibonisa isithembiso esibalulekileyo kunye nezinga le-CR ye-100%, i-58% yokuphendula ngokukhawuleza kwangethuba kunye nokunciphisa okubonakalayo kokusetyenziswa kwe-chemotherapy enetyhefu kunye nemitha. I-EFS / OS ukuza kuthi ga ngoku yi-100% kunye nexesha lokulandelela eliphakathi elingaphezu kweminyaka eyi-3.5.
UNjing Andrew Evens – HOLISTIC Hodgkin Lymphoma International Study.
UNjingalwazi Evens lilungu elisebenzayo leHoLISTIC (Hodgkin Lymphoma International Study for Individual Care) – imanyano yamazwe ngamazwe edibanisa iqela leengcaphephe ezahlukeneyo kwihlabathi jikelele ukuba lifunde ngemiba ebalulekileyo ye-Hodgkin lymphoma prognosis, epidemiology, unyango, ukusinda kunye neziphumo zempilo. kuwo onke amaqela eminyaka. Badibanisa idatha yesigulana somntu ngamnye kwizilingo zeklinikhi zangoku ezingaphezulu kwama-20 ezivela kuMntla Melika kunye neYurophu yayo yonke iminyaka kunye ne-6 yamaziko kunye nengingqi ye-Hodgkin lymphoma registries, kunye nenkqubo enkulu ye-oncology yoluntu. Injongo yabo kukuphucula ukuthathwa kwezigqibo kubantwana kunye nabantu abadala kwizigulane ze-Hodgkin lymphoma kunye nababoneleli, banikwe ukhetho olwandisiweyo zonyango kunye nokungabikho kwedatha epheleleyo ebukhali kunye nexesha elide.
UGqr Stephen Ansell kunye noDeborah Sims – Hodgkin Lymphoma.
UGqr Ansell yingcali ekhokelayo kwi-non-Hodgkin lymphoma kunye ne-Hodgkin lymphoma kwiKliniki yaseMayo, eMelika. UGqr Ansell uthethe ngeHodgkin lymphoma – iseshini yonyango lwangaphambili e-ASH awayesandula ukuya kuyo. Iseshoni ibonise ulingo lwezonyango apho kuye kwasetyenziswa ngakumbi kwiinoveli zonyango kwi-front-line setting, apho ukongeza i-Brentuximab Vedotin kunye ne-PD-1 inhibitor kunye nokunciphisa enye ye-chemotherapy eqhelekileyo eyayiyi-bleomycin, ibonise iziphumo ezibalaseleyo. Iziphumo zanciphisa ubuthi kwizigulane ezifumana olu nyango xa kuthelekiswa nonyango oluqhelekileyo. Unyango oluqhelekileyo kwi-Hodgkin lymphoma luphezulu kuwo onke amazinga okuphendula apho malunga ne-90% yesigulana sifikelela kwimpendulo epheleleyo ye-metabolic. Ulingo oluninzi kwi-Hodgkin lymphoma okwangoku lujolise ekunciphiseni iprofayili yetyhefu kunye neziphumo zamva kwezi zigulana.
I-Lymphoma yoMmandla oMda
UGq Sasanka Handunetti – iSigaba sesi-II soPhononongo kwi-Lymphoma yoMmandla oBuyelwe kwakhona okanye oLawulayo.
UDkt Handunetti uxoxe ngenkcazo yepowusta evela kwiqela likaPeter MacCallum Cancer Centre ngexesha lentlanganiso yokusetyenziswa kwe-ibrutinib ngokudibanisa ne-venetoclax kwizigulane ezine-refractory zone Lymphoma (MZL). I-MZL yintlupheko enganyangekiyo ukuba akukho mgangatho wonyango wokunyamekela kwi-relapsed or refractory setting. Omabini la mayeza abonwe ukuba anobungqina bomsebenzi kunye nokunyamezela njenge-monotherapies (i-agent enye) kwaye olu pho nonongo lujolise ukuvavanya impendulo njengonyango oludibeneyo.
I-Central Nervous System Lymphoma
UGqr Katherine Lewis – Primary Central Nervous System Lymphoma (PCNSL).
UGqr Lewis uxoxe ngenkcazo yepowusta kwi-ASH 2019 ejonge iziphumo zezigulane ezine-primary or secondary central nervous system (ingqondo kunye nomqolo) lymphoma ephathwa nge-Ibrutinib (BTK inhibitor). Le yi-lymphoma enqabileyo kunye nendlongondlongo apho eli qela lesigulana linesifo esibi kakhulu kwaye lihlala linyangwa ngendibaniselwano yerejimeni yechemotherapy. Olu luphononongo oluhlaziyiweyo oluqokelele ulwazi oluvela kulo lonke elase-Australia naseNew Zealand kwizigulane ze-16 eziye zaphathwa nge-monotherapy i-Ibrutinib kwi-relapsed setting / refractory setting. Nangona inani elincinci lezigulane, iziphumo zazithembisa, kunye namazinga okuphendula ukuya kwi-81%.
Waldenstrom's Macroglobulinemia
UNjing Mathias Rummel – iMacroglobulinemia kaWaldenstrom kunye nolingo lwe-StiL.
Igubungela iziphumo zeminyaka emi-2 emva kophononongo lwe-StiL lujonge ukugcinwa kweRituximab vs i-observation post bendamustine-rituximab. Iziphumo zibonisa ukuba i-rituximab yolondolozo ayiphuculi impilo yonke. UProf Rummel ukwabonelela ngesishwankathelo solawulo lwangoku lweWM.
T-cell Lymphoma
I-Peripheral T-cell Lymphoma
UGqr Jasmine Zain, MD - uxoxa ngezifundo ezichukumisayo kwi-PTCL ezinikezelwe e-ASH 2019.
(Enkosi kwi-OBRoncology).
UGqr. Zain, uMlawuli weNkqubo ye-T-cell Lymphoma, iSebe le-Hematology kunye ne-Hematopoietic Cell Transplantation, i-Toni Stephenson Lymphoma Centre, iSixeko seThemba, ixoxa ngezifundo ezinomdla kakhulu kunyango lwe-peripheral T-cell lymphoma (PTCL) enikezelwa kwi-ASH. 2019.
UGqr Jasmine Zain – Luye lwavela njani unyango lweperipheral T-cell lymphoma.
(Enkosi kwi-OBRoncology).
UGqr. Zain, uMlawuli weNkqubo ye-T-cell Lymphoma, iSebe le-Hematology kunye ne-Hematopoietic Cell Transplantation, i-Toni Stephenson Lymphoma Centre, iSixeko seThemba, iqwalasela indlela i-peripheral T-cell lymphoma (PCL) yonyango iguquke ngayo kwiminyaka yamuva.
UGqr Jasmine Zain – Iindlela ezintsha zokunyanga i-PTCL kubandakanywa unyango lwe-CAR T-cell.
(Enkosi kwi-OBRoncology).
UGqr Zain, uMlawuli weNkqubo ye-T-cell Lymphoma, iSebe le-Hematology kunye ne-Hematopoietic Cell Transplantation, i-Toni Stephenson Lymphoma Centre, iSixeko seThemba, isixelela ngezinye iindlela ezinoveli ekuphuhliseni unyango lwe-peripheral T-cell lymphoma ( PTCL).
UGq Timothy Illidge, ucacisa injongo yokujolisa kwi-PTCL.
(Enkosi kwi-OBRoncology).
UDkt Illidge, uNjingalwazi we-Targeted Therapy kunye ne-Oncology, iCandelo leSayensi yeCancer, iSibhedlele saseChristie, iYunivesithi yaseManchester, ichaza injongo yokujolisa kwi-peripheral t-cell lymphoma (PTCL).
